TRACK RECORD

PERSONAL INFORMATION

WORK EXPERIENCE

<ul> <li>Dates (from – to)</li> </ul>	01/11/2021 – present
<ul> <li>Name and address of employer</li> </ul>	University of Siena, Via Banchi di Sotto 55, 53100 Siena, Italy
<ul> <li>Type of business or sector</li> </ul>	University
<ul> <li>Occupation or position held</li> </ul>	Full Professor of Microbiology
<ul> <li>Main activities and responsibilities</li> </ul>	<b>Teaching</b> : Microbiology and Virology, Laboratory Medicine for MD, Pharmacists, Lal Technicians, Biotechnologists.
	Hospital duties: Conventional and molecular diagnostics in virology, set up and running an HIV & Hepatitis dedicated service.
	<b>Research</b> : Development of molecular diagnostics applied to human viral infections, particularly HIV and hepatitis viruses, antiviral drug resistance, antiviral drug development.
Dates (from – to)	01/11/2002 - present
Name and address of employer	University of Siena, Via Banchi di Sotto 55, 53100 Siena, Italy
Type of business or sector	University
Occupation or position held	Associate Professor of Microbiology
Main activities and responsibilities	<b>Teaching</b> : Microbiology and Virology, Laboratory Medicine for MD, Pharmacists, Lal Technicians, Biotechnologists.
	Hospital duties: Conventional and molecular diagnostics in virology, set up and running an HIV & Hepatitis dedicated service.
	<b>Research</b> : Development of molecular diagnostics applied to human viral infections, particularly HIV and hepatitis viruses, antiviral drug resistance, antiviral drug development.
• Dates (from – to)	15/05/1990 - 30/10/2002

<ul> <li>Dates (from – to)</li> </ul>	15/05/1990 – 30/10/2002
<ul> <li>Name and address of employer</li> </ul>	Azienda Ospedaliera Senese (formerly USL 30), Policlinico S. Maria alle Scotte,
	Viale Bracci 1, 53100 Siena, Italy
<ul> <li>Type of business or sector</li> </ul>	University Hospital
<ul> <li>Occupation or position held</li> </ul>	Biologist at the Service of Microbiology and Virology
<ul> <li>Main activities and</li> </ul>	Development and use of molecular diagnostics applied to human viral infections
responsibilities	

<ul> <li>Dates (from – to)</li> </ul>	01/04/1988 – 31/03/1990
<ul> <li>Name and address of</li> </ul>	ENI, Rome, Italy
employer	
<ul> <li>Type of business or sector</li> </ul>	Energy
<ul> <li>Occupation or position held</li> </ul>	Fellowship
<ul> <li>Main activities and</li> </ul>	Program "Lymphokines and synthetic vaccines", topic "Adenovirus as a vector for
responsibilities	influenza vaccine"

<ul> <li>Dates (from – to)</li> </ul>	01/01/1988 – 31/03/1988
Name and address of	Ciba-Geigy S.P.A., Origgio (VA), Italy
employer	Drug manufacturer
<ul> <li>Type of business or sector</li> <li>Occupation or position held</li> </ul>	Fellowship
Main activities and	Isolation and characterization of influenza virus from clinical specimens in a trial
responsibilities	evaluating the use of ribavirin as an anti-influenza agent

## EDUCATION AND TRAINING

<ul> <li>Dates (from – to)</li> </ul>	01/11/1995 – 31/10/1999
<ul> <li>Name and type of organisation providing education and training</li> </ul>	University of Siena
<ul> <li>Principal subjects/occupational skills covered</li> </ul>	Advanced Microbiology and Virology, particularly clinically oriented topics.
<ul> <li>Title of qualification awarded</li> </ul>	Specialty School in Microbiology and Virology.
<ul> <li>Level in national classification</li> </ul>	Full marks cum laude
(if appropriate)	
<ul> <li>Dates (from – to)</li> </ul>	01/11/1981 – 31/10/1985
<ul> <li>Name and type of organisation providing education and training</li> </ul>	University of Siena
Principal subjects/occupational skills covered	General Biology, particularly Microbiology. Two-year practice at the Laboratory of Virology working with viral diagnostics.
Title of qualification awarded	Degree in Biological Sciences.
Level in national classification     (if appropriate)	Full marks cum laude.

## Personal skills AND COMPETENCES Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas.

MOTHER TONGUE	ITALIAN
OTHER LANGUAGES • Reading skills • Writing skills • Verbal skills	ENGLISH Excellent (C1) Excellent (C1) Excellent (C1)
Social skills AND COMPETENCES Living and working with other people, in multicultural environments, in positions where communication is important and situations where teamwork is essential etc.	<ul> <li>Set-up, maintenance and updating of an HIV dedicated laboratory and research group at the Department of Molecular Biology of the University of Siena since 1990.</li> <li>Supervisor of more than 30 thesis for the degree in Biological Sciences, in Biotechnology and for the Master in Microbiology and Virology.</li> <li>Supervisor of more than 20 PhD students, teaching at the University of Siena since 1992 through lessons, laboratory practice and involvement in research projects.</li> <li>Continuous cooperation with infectious diseases clinics in Italy since 1990.</li> <li>Continuous cooperation with many HIV international experts from academy and industry through conferences, workshops and research projects since 1995.</li> <li>Invited speakers at 125 CME events, 38 national and international conferences and 11 roundtables and consensus meetings.</li> <li>Scientific peer-reviewed publications indexed in PubMed: 265. Impact factor: 1077.546. H index: 32 (Scopus).</li> </ul>
ORGANISATIONAL SKILLS AND COMPETENCES Coordination and administration of people, projects and budgets at work	<ul> <li>Principal investigator in many HIV related research projects together with other academic scientists from Italy and abroad and with pharmaceutical companies.</li> <li>Familiarity with allocation of resources and budgeting, selection of project dedicated staff with attention at team working capabilities.</li> </ul>
	<ul> <li>Membership of national and international research consortia</li> <li>2002-ongoing. President of the Scientific Board of the Antiretroviral Resistance Cohort Analysis (www.dbarca.net), a curated collection of HIV treatments and HIV drug resistance data throughout Italy.</li> <li>2003-2007. Founding member and then consultant of the Resistance Response Database Initiative (www.hivrdi.org), an international consortium dedicated to the development of artificial intelligence systems for optimizing anti-HIV therapy.</li> <li>2009-2011. Member of the OSCAR and DIVA national network involving laboratories developing molecular systems for the analysis of HIV coreceptor tropism.</li> <li>2009-ongoing. Founding member and then permanent member of the Steeribg Committee of the EuResist Network (www.euresist.org), a European consortium (plus non-European partners) for research studies based on large datasets related to anti-HIV therapy.</li> <li>2010. Expert member in the European Centre for Disease Prevention and Control (ECDC) tender "Public Health Value of HIV ARV Resistance monitoring within the EU/EEA" (Publication Reference: OJ/2010/02/22-PROC/2010/008).</li> <li>2011-ongoing. Member of the Steering Committee of the European HIV coreceptor study group (https://www.euresist.org/eucohiv), a research consortium aimed at studying HIV coreceptor tropism and the use of coreceptor antagonists.</li> <li>2012-2016. Coordinator of the Italian HLA Virological-Clinical Network, a national network of laboratories involved in the development of HLA-related</li> </ul>

assays for optimization of antivirtal therapy.

- 2013-2019. Member of the collaborative group for the management of the INIMAGE (Integrase Inhibitors Management by Genotype) national study.
- 2015-2020. Italian delegate for the European Society for Translational Antiviral Research (ESAR, <u>www.esar-society.eu</u>), a scientific society for the study of virus evolution and its pathogenetic implications.
- 2016-ongoing. Member of the Scientific Board and Coordinator of the Virology Group in the VIRONET-C collaboration (<u>https://www.vironetc.org/</u>), a national network of laboratories and clinics studying anti-HCV treatment.
- 2017-ongoing. Member of the Steering Committee of the INTEGRATE project, an activity coordinated by the EuResist consortium to optimize the use of HIV integrase inhibitors across Europe.
- 2018-ongoing. Member and Coordinator of the HIV DNA Network, a national initiative for setup and harmonization of quantitative HIV DNA assays.

### Congress and Conference chairmanship

- 1. Aggiornamenti in tema di resistenze agli antiretrovirali: dal genotipo alla risposta virologica al trattamento. Firenze, Villa Le Rondini, 10 Aprile 2003.
- 2. Attualità in tema di interpretazione dei test di resistenza agli antiretrovirali. Roma, Università Cattolica del Sacro Cuore, 31 marzo - 1 aprile 2004.
- 3. HAART 10 anni dopo. Siena, Certosa di Pontignano, 6 Giugno 2006.
- 4. Biomedical informatics for optimised treatment of infectious diseases. Helsinki, November 22, 2006.
- 5. First Workshop on Italian HIV Cohorts. Siena, Certosa di Pontignano, October 9th, 2007.
- 6. EuResist Moscow Meeting. Moscow, Borodino Hotel, December 15-16, 2008.
- 7. EuResist Tallinn Meeting. Tallinn, Estonia, April 3, 2008.
- 8. HIV drug resistance genotyping. A practical course. Kenya Medical Research Institute, Nairobi, February 21-25, 2011.
- 9. HIV drug resistance genotyping. A practical course. Kenya Medical Research Institute, Nairobi, February 20-22, 2012.
- 10. ARCA Mentor School. Siena, 27-28 Maggio 2015.
- 11. Presente e futuro degli INSTI nella pratica clinica. Siena, 4 Ottobre 2016.
- 12. ARCA Mentor School. Siena, 6-7 Ottobre 2016.
- 13. 9th Italian Conference on AIDS and Antiviral Research (ICAR 2017). Siena, 12-14 Giugno 2017.
- 14. ARCA Mentor School. Siena, 20-21 settembre 2017.
- 15. Le terapie antiretrovirali a due farmaci. Un cambio di paradigma? Firenze, 5 Aprile 2018.
- Scuola di Alta Formazione in Virologia Clinica VIKT 2018. Siena 24-25 settembre 2018.
- 17. ARCA Mentor School. Sioena, 18-19 Settembre 2019.
- 18. ARCA Factory. Web, 28-29 Settembre 2020.

# Membership in the organizing/scientific committee of national and international congresses

- 1. Congress of the Italian Society for Virology. 2010-2015. Secretary of the Society from 10/2012 to 11/2015.
- 2. National Congress of the Società Italiana di Virologia Italian Society for Virology. Consultant Member and Member of the Scientific Committee since 2016.
- 3. ICAR, Italian Conference on AIDS and Antiviral Research. Member of the Scientific and/or Program Committee since 2015.
- 4. European Meeting on HIV and Hepatitis. Member of the Scientific Committee since 2012.

#### Grants

1. 1990-1995. VII, VIII and IX AIDS Project, Istituto Superiore di Sanità, Ministry of Health, Rome.

2.	1994-1996. I, II and III Project on Antiretroviral Therapy, Istituto Superiore di Sanità, Ministry of Health, Rome.
3.	1997-2006. I, II, III and IV National AIDS Programme, Istituto Superiore di Sanità,
4	Ministry of Health, Rome. 2004. INFOBIOMED (Network of Excellence of the European Community, IST-
	507585): "Biomedical Informatics to Support Individualised Healthcare".
5.	2005. PRIN 2005 (Ministry of University and Research, Italy): "Development and
	use of a dedicated database for the study of genotypic antiretroviral resistance in vivo: integrated management of the factors involved in antiretroviral resistance".
6.	2005. Targeted Research 2005 (Ministry of Health, Italy): "Management of HIV
7	drug resistance in modeling novel antiretroviral therapy strategies" 2005. University Research Plan 2005 (University of Siena): "Development of a
7.	surveillance system for the circulation of different human immunodeficiency virus
	type 1 (HIV-1) subtypes and recombinant forms"
8.	2006. EuResist (STREP of the European Community, IST-2004-027173), "Integration of viral genomics with clinical data to predict response to anti-HIV
	treatment"
9.	2008. PRIN 2008 (Ministry of University and Research, Italy): "Development of
10	laboratory assays for advanced monitoring of HIV drug resistance" 2009. CHAIN ("Collaborative HIV and Anti-HIV Drug Resistance Network", Large
10.	scale project of the European Community, Grant Agreement number 223131).
11.	2009. EDCTP Joint Program Activities, "Integrated training activities and IT
12	infrastructures to improve capacities in Eastern African area" 2009. AIDS Program 2009, Italy. "Implementation of an HIV drug resistance
12.	database as a platform for resistance related research proposals and for
10	advanced HIV genotype interpretation" (grant 40h81).
13.	2012. Fellowship Program Gilead. The role of the viral reservoir and residual viremia in patients switched to raltegravir plus 2 NRTIs after virological
	suppression.
14.	2013. THINPAD (FP7-HEALTH-2013-INNOVATION-2): "Targeting the HIV-1
15.	Nucleocapsid Protein to fight Antiretroviral Drug Resistance". 2015. Fellowship Program Gilead. HBV DNA distribution in PBMC and plasma
	from HBV inactive carriers and patients with occult HBV infection (OBI).
16.	2016. Tuscany Region FAS-Salute: "UNAVIR: a novel strategy to combat multiple viral infections with one antiviral".
17.	2017. Fellowship Program Gilead. Changes in total and integrated HIV-1 DNA
	following treatment deintensification.
18.	2018. Tuscany Region POR-FESR 2014-2020 "PANVIR.NET: preclinical development of innovative PANVIRal antivirals in a specialized regional
	NETwork".
19.	2019. CARE (H2020 Research and Innovation action: H2020-SC1-2018-Single-
	Stage-RTD - SC1-BHC-21-2018): "Common Action against HIV/TB/HCV across the Regions of Europe"). Grant agreement ID: 825673.
20.	2019. PRIN 2017: "ORIGINALE CHEMIAE in Antiviral Strategy - Origin and
	Modernization of Multi-Component Chemistry as a Source of Innovative Broad Spectrum Antiviral Strategy". Prot. 2017BMK8JR.
21.	2019. AIFA 2017 Call for Independent Drug Research: "OPTIMA - Strategies to
	Contain HIV Drug-Resistance Emergence in Virologically Suppressed Patients
	Requiring Antiretroviral Therapy Optimization: Unraveling the Role of Mutational Burden in PBMCs". AIFA Code TRS-2018-00001336.
22.	2020. Tuscany Region Health Call 2018: TUSCAVIR (Tuscany Antiviral
	Research Network).
23.	2020. Tuscany COVID19 Call 2020: APICE (Antibodies and Peptides Inhibiting Coronavirus Entry).
24.	2020. Intesa San Paolo Bank COVID-19 Call: Blocking Coronavirus infection:
	developing inhibitors of SARS-CoV-2 protease and multifunctional compounds
	interfering with virus entry and replication.

	<ol> <li>25. 2021. EuCARE (HORIZON-HLTH-2021-CORONA-01 — COVID19 - HERA Incubator): "European Cohorts of Patients and Schools to Advance Response to Epidemics".</li> <li>26. 2021. PRIN 2020: Multidisciplinary Assessment of the blood and gut-associated HIV Reservoir and Immunity following Switch from 3-drug to 2-drug Antiretroviral regimens in virologically suppressed patients (MARISA).</li> </ol>
TECHNICAL SKILLS AND COMPETENCES With computers, specific kinds of equipment, machinery, etc.	<ul> <li>Computers. Advanced use of the Windows operating system. Excellent knowledge of the main office suites. Advanced knowledge of DNA/protein analysis software packages (DNAstar, Vector NTI, Mega, BioEdit). Good knowledge of statistical packages (SSPS, Statistica, Sigmastat). Continuous use of web resources such as medical education, scientific databases (e. g. PubMed, GenBank, NCBI, LANL). Basic knowledge of HTML and web design. Good knowledge of relational databases (Oracle, MySQL). Advanced programming skills in Visual Foxpro.</li> <li>Familiarity with many basic biomedical laboratory equipment and specialized microbiology and virology laboratory equipment.</li> </ul>

ADDITIONAL INFORMATION	Associate Editor for the following journals
	BMC Infect Dis
	Deviewer far the fallowing existilia is unals
	Reviewer for the following scientific journals
	AIDS, AIDS Reviews, Antimicrobial Agents and Chemotherapy, Antiviral Therapy,
	BMC Infectious Diseases, Clinical Chemistry, Clinical Chemistry and Laboratory
	Medicine, Clinical Infectious Diseases, Clinical Microbiology and Infection, CNS Drugs, Current HIV Research, EClinicalMedicine, Epidemiology and Infection, HIV
	Clinical Trials, HIV Medicine, Indian Journal of Medical Research, International
	Journal of Antimicrobial Agents, Journal of Antimicrobial Chemotherapy, Journal of
	Clinical Microbiology, Journal of Infectious Diseases, Journal of the International AIDS
	Society, Journal of Medical Virology, Journal of Translational Medicine, Journal of
	Virological Methods, Lancet Infectious Diseases, Lacet Microbes, PLoS
	Computational Biology, PLoS ONE, Retrovirology, Scientific Reports, Virology, Virus
	Research.
	Awards
	<ol> <li>2008. Scientific coordinator of the EuResist project (FP6-2004-IST-4: Integration of viral genomics with clinical data to predict response to anti-HIV treatment),</li> </ol>
	awarded the Project of the Month honor in November 2008.
	<ol><li>2009. Winner of the Computerworld Honors Program (Honoring those who use information technology to benefit society) with a case study based on the</li></ol>
	EuResist anti-HIV treatment response prediction engine.
	Patents
	<ol> <li>Antiretroscan, 30/10/2002. Method for prediction of susceptibility to antiretroviral drugs. Deposit number RM2002A000544.</li> </ol>
	2. HIV-1 nucleocapsid inhibitors, 24/10/2016. Patent n. 16186511.8-1452.

Date: 14/02/2022

I hereby authorize the handling of my personal data pursuant to the Personal Data Protection Code – Legislative Decree n. 196/2003.

